Treatment
Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） clinical trials
We’re tracking 2 recruiting studies that include Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, each written for real people, not researchers, below.
Recruiting studies
- NCT06375486RecruitingPhase 2
Ivonescimab and HAIC for Unresectable Liver Cancer
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07686575Recruiting
Ivonescimab with chemo for advanced mouth or throat cancer
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
Guangzhou, GuangdongAges 18–80
What Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） is being studied for
Conditions with recruiting Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） studies.
Common questions
- Are there clinical trials studying Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）?
- Yes. Clin2 currently lists 2 recruiting studies that include Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.